Month: May 2022

Ashvattha Therapeutics to Present at UBS Global Healthcare Conference 2022

by

REDWOOD CITY, Calif., May 5, 2022 – Ashvattha Therapeutics, (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced that Jeffrey Cleland, Ph.D., Chairman, CEO & President of Ashvattha, will provide a corporate overview followed by a moderated Q&A at the UBS Global Healthcare Conference 2022 taking place in New York, NY, May … Read more

Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous anti-VEGF wet AMD and DME Candidate at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

by

Data showed single subcutaneous doses of D-4517.2 were safe and well tolerated in healthy subjects D-4517.2 exposure in healthy subjects translates to efficacious doses in choroidal neovascularization (CNV) in mouse model Initiation of Phase 2 study evaluating D-4517.2 in patients with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME) expected in mid-2022 … Read more